Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT study of PARIET versus NEXIUM for gastro-oesophageal reflux disease
ACTRN12607000006448Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rabeprazole and esomeprazole in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Resolution of heartburn and regurgitation symptoms after 4 weeks. Started Nov 2006; status: completed.
02
Drugs
rabeprazoleesomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on ACTRN12607000006448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000006448.